Patient Selection for Cytoreductive Surgery

Travis E Grotz; Keith F Fournier; Paul F Mansfield

doi:10.1016/j.soc.2018.02.012

Patient Selection for Cytoreductive Surgery

Surg Oncol Clin N Am. 2018 Jul;27(3):443-462. doi: 10.1016/j.soc.2018.02.012.

Authors

Travis E Grotz¹, Keith F Fournier², Paul F Mansfield²

Affiliations

¹ Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA; Department of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA. Electronic address: grotz.travis@mayo.edu.
² Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.

PMID: 29935682
DOI: 10.1016/j.soc.2018.02.012

Abstract

The peritoneal malignancies span the biologic spectrum of aggressiveness from the indolent growth pattern and superficial nature of well-differentiated mucinous appendiceal adenocarcinoma to the rapidly growing and invasive nature of poorly differentiated signet ring cell adenocarcinomas of the appendix, colon, and stomach. An understanding of the biology, distribution, and volume of disease is critical to appropriately selecting patients for cytoreduction and HIPEC with the goal of long-term survival. Herein the authors discuss appropriate the evaluation and selection of patients for with peritoneal surface malignancies for cytoreduction and HIPEC.

Keywords: Cytoreduction; HIPEC; Outcomes; Patient selection; Predicting; Prognostic factors.

Publication types

Review

MeSH terms

Adenocarcinoma, Mucinous / pathology
Adenocarcinoma, Mucinous / surgery*
Appendiceal Neoplasms / pathology
Appendiceal Neoplasms / surgery*
Cytoreduction Surgical Procedures / methods*
Humans
Patient Selection*
Peritoneal Neoplasms / secondary
Peritoneal Neoplasms / surgery*